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Introduction {#sec1}
============

Pluripotent stem cells (PSCs) can differentiate into any bodily cell type. Somatic cells can also be reprogrammed to pluripotency by overexpression of "Yamanaka factors," generating inducible PSCs (iPSCs) ([@bib24]). Optimization of these technologies over the past 10 years has enabled the safe generation of patient-specific iPSCs for prospective clinical applications. Now the major hurdle in the translational application of iPSC technologies is developing strategies to differentiate PSCs into clinically relevant functional cell types.

Adult hematopoietic stem cells (HSCs) reside in the bone marrow (BM) and have the unique ability to reform the entire blood system ([@bib6]). HSC function is defined by a cell-intrinsic transcriptional program as well as cell-extrinsic signaling emanating from the BM microenvironment. Long-term HSC function provides the basis of BM transplantation, a curative therapy for a range of hematological disorders. Derivation of functional HSCs from PSCs has therefore been a long-sought goal of regenerative medicine ([@bib25]). However, we are currently unable to generate truly functional HSCs from PSCs *in vitro*. This is likely due to our inability to fully recapitulate the complex and temporally dynamic *in vivo* microenvironmental signaling program that specifies HSCs during development ([@bib10]). In mice, transplantable HSCs emerge from hemogenic endothelial (HE) precursors, notably in the dorsal aorta ([@bib27]). Expression of the transcription factor (TF) *Runx1* can be used to track this process ([@bib13]); live-cell imaging has captured hematopoietic stem/progenitor cell (HSPC) formation at sites of *Runx1*^+^ HE cells ([@bib2], [@bib3]).

Certain attempts to generate HSCs thus far have used transgene overexpression to either direct the differentiation of PSCs, or alternatively, to transdifferentiate other somatic cell types. Several approaches have been reported to generate hematopoietic cells *in vitro* ([@bib5], [@bib17], [@bib18]). In two very recent reports, conversion of mouse and human endothelial cells to engraftable HSCs was achieved by overexpression of several TFs ([@bib20], [@bib9]).

In another study, [@bib16] reported that overexpression of three TFs (*Gfi1b*, *c-Fos*, and *Gata2*) could transdifferentiate mouse fibroblasts into HE-like intermediates that could further mature into hematopoietic progenitor cells (HPCs). However, fully functional HSCs were not generated by this method.

As an alternative, we (and others) have previously demonstrated proof of concept for the *in vivo* generation of fully functional HSCs from PSCs via teratoma formation ([@bib22], [@bib1]). However, our first-generation *in vivo* differentiation system ([@bib22]) had several limitations: (1) PSCs needed to be co-injected with OP9 stromal cells and hematopoietic cytokines (SCF and TPO) administered via micropump; (2) we could not identify the site of HSC emergence; and; (3) HSC formation was slow, taking 2--3 months. Here, we systemically overcome these limitations and provide an optimized *in vivo* HSC formation protocol. Furthermore, we demonstrate that *in vivo* overexpression of *Gfi1b*, *c-Fos*, and *Gata2* during teratoma formation is sufficient to generate functional long-term HSCs.

Results {#sec2}
=======

*Gfi1b*, *c-Fos*, and *Gata2* Overexpression Induces Hematopoietic Cell Formation in Teratomas {#sec2.1}
----------------------------------------------------------------------------------------------

Teratomas contain tissues from all three germ layers, and we previously demonstrated that teratomas can generate HSCs ([@bib22]). However, this required co-injection of OP9 stromal cells and continuous administration of cytokines ([@bib22]). We hypothesized that induction of TFs related to HSCs and/or the HSC microenvironment could improve HSC generation in teratomas. To this end, we investigated three distinct TF combinations: (1) *Gfi1b*, *c-Fos*, and *Gata2* (*GFG*), which have been reported to generate HE-like cells and HPCs from fibroblasts ([@bib16]); (2) *Erg*, *HoxA9*, and *Rora* (*EAR*), which have been reported to generate HPCs during PSC embryoid body formation ([@bib5]), and (3) *Foxc1*, reported to be highly expressed in *CXCL12*-abundant reticular (CAR) cells, an important component of the HSC BM niche ([@bib15]).

To enable the identification of iPSC-derived HSCs, we first established iPSCs from a C57BL/6-Ly5.1 mouse to allow immunophenotypic discrimination from C57BL/6-Ly5.2 host mouse blood cells. Next, we cloned the above TFs into a doxycycline (Dox)-inducible (Tet-On) lentivirus expression vector ([Figure 1](#fig1){ref-type="fig"}A). Stable iPSC lines were generated and Dox-inducible transgene expression was confirmed using qPCR ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Next, we injected C57BL/6-Ly5.1 iPSCs (2 × 10^6^) subcutaneously into host C57BL/6-Ly5.2 mice, and administered Dox for 4 weeks once teratomas reached \>2 cm in diameter (6--8 weeks post-injection) to induce TF expression ([Figure 1](#fig1){ref-type="fig"}B). Importantly, this was undertaken without co-injection of stromal cells or cytokines.Figure 1Screening Transcription Factor Expression for Hematopoiesis within Teratomas(A) Schematic diagram of the doxycycline (Dox)-inducible system for the expression of transcription factor (TF) combinations.(B) Strategy to induce hematopoietic cells from lentivirally transduced iPSCs through teratoma formation. Dox was administrated for 4 weeks after teratoma size reached 2 cm in diameter, after which teratomas were collected for histological analysis.(C) Representative H&E-stained teratoma sections, with morphological features labeled. Trabecular bone-like structure, TB (and black arrows); bone marrow cells, BMCs (and red arrows); endothelial cells, ECs (and white arrows); epithelial, EPCs (and black arrows).(D) Representative flow cytometric plots of CD45.1 and CD45.2 expression in peripheral blood (PB) from teratoma-bearing Ly5.2 host mice at 14--16 weeks after Ly5.1 iPSC injection.(E) Average percentage of CD45.1^+^ PB cells in host mice. Data are the means ± SD from two independent experiments (n = 6). ^∗^p \< 0.05.(F) Average percentages of hematopoietic cell lineages within the CD45.1^+^ population in (E). Gr-1^+^, granulocytes; Mac-1^+^, macrophages; B220^+^, B cells; CD4^+^, CD4^+^ T cells; and CD8^+^, CD8^+^ T cells. Data are means ± SD from two independent experiments (n = 3).

After the 4-week Dox exposure, we analyzed the peripheral blood (PB) of engrafted mice by flow cytometry and the teratoma by histology ([Figure 1](#fig1){ref-type="fig"}B). We observed distinct differences between teratomas generated in the different experimental regimens ([Figures 1](#fig1){ref-type="fig"}C and 1D). For example, the *GFG* iPSC-derived teratomas contained a large number of endothelial and epithelial-like cells by H&E staining ([Figure 1](#fig1){ref-type="fig"}C). By contrast, *Foxc1*-derived teratomas formed bone cortices, cartilage, and BM-like cells ([Figure 1](#fig1){ref-type="fig"}C). While CD45.1^+^ donor-derived blood cells were not detected in the host PB following injected with wild-type iPSCs or *Foxc1* iPSCs, both *EAR* iPSCs and *GFG* iPSCs reconstituted multi-lineage hematopoiesis 14--18 weeks post-injection ([Figures 1](#fig1){ref-type="fig"}D and 1E), with *GFG* iPSCs generating approximately 2-fold more hematopoietic cells ([Figures 1](#fig1){ref-type="fig"}E and 1F). These data demonstrate that *GFG* iPSC-derived teratomas differentiate into hematopoietic cells more efficiently compared with the other groups.

To evaluate the potential consequences of the *GFG* cassette on HSCs, we generated *GFG* transgenic mice from *GFG* embryonic stem cells. Leaky expression could not be detected ([Figure S1](#mmc1){ref-type="supplementary-material"}B), and no difference in colony-forming ability was seen ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Reactivation of the reprogramming factors could also not be detected in iPSC-derived CD45^+^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}D).

Identification of Hemogenic Endothelium within GFG iPSC-Derived Teratomas {#sec2.2}
-------------------------------------------------------------------------

Given that *GFG* expression directly induces HE-like cells from mouse fibroblast *in vitro* ([@bib16]), we hypothesized that endothelial cells (ECs) within the *GFG* iPSC-derived teratomas ([Figure 2](#fig2){ref-type="fig"}A) might in fact resemble HE cells. By co-staining with Cytokeratin and CD31, we could identify CD31^+^ endothelial-lined cystic structures, which were also CD144/VE-cadherin^+^ ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). We further confirmed the presence of *Runx1*-expressing ECs in *GFG* teratoma sections by immunostaining for Runx1 and CD31 ([Figure 2](#fig2){ref-type="fig"}B). Moreover, we could even identify hematopoietic cell clusters budding from these ECs ([Figure 2](#fig2){ref-type="fig"}B). CD45^+^ hematopoietic cells could also be identified within the endothelial structures, suggesting teratoma vasculature was perfused with blood ([Figure S2](#mmc1){ref-type="supplementary-material"}C).Figure 2Identification of Hematopoietic-Generating Tissue in Teratomas(A) Representative images from *GFG* teratoma sections stained with H&E. These tissues contain a large number of endothelial-like cells (ECs), annotated with black arrows. Hematopoietic cells (HCs) appearing to directly bud from ECs are annotated with white arrows.(B) Representative images from *GFG* iPSC-derived teratoma sections stained with Runx1 and CD31. Runx1^+^ cells were detected by DAB (brown color) and CD31^+^ were detected by Bajoran purple (Purple color), with sites of double staining identified as putative sites of hematopoietic cell emergence, as marked by white arrows.(C) Representative images of teratoma tissue clearing in chemical cocktails and computational analysis (CUBIC); non-cleared on the left, cleared on the right.(D) Localization of *eR1*^+^ cells (green) and DAPI (blue) in 2D reconstructed image between *eR1*-derived and *eR1*-*GFG*-derived teratoma.(E) Localization of *eR1*^+^ cells (green) and DAPI (blue) in 3D reconstructed images between *eR1*-derived and *eR1*-*GFG*-derived teratoma.(F) Representative flow cytometric plots for CD45 and GFP expression in the teratoma from *eR1*-EGFP iPSC-derived teratomas.(G) Percentage GFP^+^CD45^+^ cells in teratomas, using gating displayed in (F) (n = 3). ^∗^p \< 0.05.

*Runx1* enhancer activity can be used to identify HE cells ([@bib23]). To study this in the teratoma, we established iPSCs from a *eR1-EGFP* transgenic reporter mouse ([@bib12]). The activity of an enhancer for *Runx1* (eR1), formerly called *Runx1+24* or *+23,* is known to specifically mark HE cells within CD31^+^ endothelium in the embryo as well as committed CD45^+^ HSPCs ([@bib14]). To comprehensively visualize all GFP^+^ cells within the teratoma, we applied tissue clearing and 3D volumetric imaging or CUBIC ([@bib21]) ([Figure 2](#fig2){ref-type="fig"}C). Using this method, we were further able to identify GFP^+^ endothelial structures within *GFG*-derived teratomas ([Figures 2](#fig2){ref-type="fig"}D and 2E). Notably, GFP^+^ cells were much more frequent within the *GFG*-derived teratomas than the controls ([Figure 2](#fig2){ref-type="fig"}E).

We further confirmed that *eR1*-*EGFP*-iPSCs were giving rise to GFP^+^CD45^+^ HSPCs by flow cytometric analysis of the teratomas. We detected a distinct GFP^+^CD45^+^ cell population, which was nearly 10-fold higher in *GFG*-derived teratomas compared with the controls (average value: control, 0.06% ± 0.02%; *GFG*, 0.8% ± 0.3%) ([Figures 2](#fig2){ref-type="fig"}F and 2G). Therefore, *GFG* expression induces *eR1*-EGFP expression within teratomas and generates GFP^+^CD45^+^ hematopoietic cells, similar to that described *in vitro* ([@bib16]). However, the low frequency of teratoma-derived blood cells in this system precluded our further analysis of HSC formation and function. It is worth noting that GFG induction in iPSCs could not induce eR1-GFP expression, or surface markers associated with HE or hematopoietic cell commitment ([Figure S2](#mmc1){ref-type="supplementary-material"}D), suggesting hematopoietic cell induction following GFG expression occurred within the context of teratoma development/differentiation.

Conditional c-Kit Deficiency Promotes Expansion of iPSC-Derived HSPCs *In Vivo* {#sec2.3}
-------------------------------------------------------------------------------

Adult HSCs take up lifelong residence in the BM. To improve teratoma-derived hematopoietic cell frequencies, we hypothesized that HSC-deficient hosts would promote expansion of iPSC-derived HSCs. HSCs can engraft in *c-Kit*-deficient mice without irradiation ([@bib4]). We therefore generated host mice with inducible, hematopoietic-specific *c-Kit* deletion by breeding C57BL/6-Ly5.2 *c-Kit*^*flox/flox*^ *Mx1-Cre* transgenic mice where *c-Kit* deletion was achieved by poly(I:C) administration ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Importantly, white blood cell, hemoglobin, and platelet counts were lower in *c-Kit*-deficient mice (*c-Kit*^Δ/Δ^) than in the controls ([Figure S3](#mmc1){ref-type="supplementary-material"}B), and the BM was hypocellular ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We further confirmed long-term multi-lineage donor reconstitution in Ly5.2 *c-Kit*^Δ/Δ^ hosts without irradiation following transplantation of 1 × 10^7^ Ly5.1 BM donor cells ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E).

Having validated a mouse model that was permissive to HSC engraftment, we next wanted to determine whether the *c-Kit*^Δ/Δ^ model could improve teratoma-derived HSC formation. We injected *GFG* iPSCs subcutaneously into *Mx1-Cre*;*c-Kit*^*flox/flox*^ host mice and administered poly(I:C) following teratoma formation (and Dox treatment) to deplete host HPSCs ([Figure 3](#fig3){ref-type="fig"}A). After 4--6 weeks, we observed a 10-fold increase in the frequency of iPSC-derived hematopoietic cells within the PB of the *c-Kit*^Δ/Δ^ hosts compared with control mice (control group, 0.02% ± 0.02%; *c-Kit* ^Δ/Δ^, 0.3% ± 0.2%) ([Figure 3](#fig3){ref-type="fig"}B). We also found similar increases in iPSC-derived cell frequencies within the BM (control group, 0.01% ± 0.001%; *c-Kit*^Δ/Δ^, 0.2% ± 0.1%) ([Figure 3](#fig3){ref-type="fig"}C). Notably, poly(I:C) did not influence the generation of teratoma-derived PB cells in wild-type mice ([Figure S4](#mmc1){ref-type="supplementary-material"}A).Figure 3*c-Kit* Deficiency Promotes Expansion of Hematopoietic Stem Cells from *GFG*-Derived iPSCs(A) Strategy to induce HSCs from iPSCs using *c-Kit* deficient host mice. iPSCs were injected subcutaneously and Dox administered for 4 weeks to induce *GFG* expression (as in [Figure 1](#fig1){ref-type="fig"}B). Host mice were then administered polyI:C at weeks 14--16. At 20 weeks, WBMCs from teratoma-bearing mice were transplanted into irradiated mice, and PB/BM chimerism tracked. Secondary transplantations were performed at 16 weeks after the primary transplantation.(B) Representative flow cytometric plots for CD45.1 and CD45.2 expression in the PB from teratoma-bearing C57BL/6 and *c-Kit*-deficient mice after 4--6 weeks poly(I:C) administration.(C) Percentage CD45.1^+^ chimerism in the PB (left) and BM (right). Data are the means ± SD from two independent experiments (n = 6). ^∗∗^p \< 0.005, ^∗^p \< 0.05.(D) Percentage of (*GFG* iPSC-derived) CD45.1^+^ PB chimerism of in primary and secondary recipient mice (n = 5).(E and F) Colony potential of 2.0 × 10^4^ host CD45.2^+^ and *GFG*-derived CD45.1^+^ BM cells of secondary recipients, after 11-day culture in Methocult. Total number of colonies displayed in (E) and colony type displayed in (F). Data are means ± SD from two independent experiments (n = 3). Colony cells were morphologically identified as neutrophils (n), macrophages (m), erythroblasts (E) and megakaryocytes (M). ^∗∗^p \< 0.005.(G) Representative flow cytometric plots and gating for the Kit^+^Sca1^+^Lineage^−^ fraction within the BM of secondary recipient mice transplanted with *GFG* teratoma-derived blood cells 24 weeks post-transplantation. *Lin*^−^, lineage negative cells; *KSL*, Lin^−^Kit^+^Sca1^+^ cells.

To assess whether these hematopoietic cells contain engraftable HSCs, we transplanted 1 × 10^7^ whole bone marrow cells (WBMCs) from teratoma-host mice into irradiated C57BL/6-Ly5.2 recipient mice ([Figure 3](#fig3){ref-type="fig"}A). We detected CD45.1^+^ PB cells in multiple lineages over 16 weeks ([Figure 3](#fig3){ref-type="fig"}D). To functionally confirm long-term HSC capacity within the original CD45.1^+^ cells, 1 × 10^7^ WBMCs from the primary recipients were transplanted into irradiated secondary recipient mice. Multi-lineage CD45.1^+^ PB cells could be detected long-term in these secondary recipients (and even in tertiary recipients), demonstrating long-term HSC activity ([Figures 3](#fig3){ref-type="fig"}D, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). In addition, we detected immunophenotypic CD45.1^+^C-KIT^+^SCA-1^+^Lineage^−^ HPSCs in the BM of secondary recipients ([Figure 3](#fig3){ref-type="fig"}G). However, we noted that a 30% reduction in colony-forming units within the CD45.1^+^ WBMC population compared with CD45.2^+^ host BM cells, suggesting teratoma-derived BM cells are not identical to normally produced BM cells ([Figures 3](#fig3){ref-type="fig"}E, 3F, [S4](#mmc1){ref-type="supplementary-material"}D, and S4E). However, these data demonstrate that *GFG* expression within teratomas generates functional HSCs that expand within *c-Kit*-deficient mice.

Transplantable Teratomas Provided Stable and Continuous Source of HSPCs {#sec2.4}
-----------------------------------------------------------------------

Finally, to improve on the time-consuming nature of these experiments, we investigated the following: (1) serial transplantation of freshly isolated teratomas and (2) use of cryopreservation of teratoma blocks. We performed transplantation of freshly isolated or cryopreserved teratoma blocks into host recipient mice ([Figure 4](#fig4){ref-type="fig"}A). In both cases, the transplanted teratomas survived and expanded ([Figure 4](#fig4){ref-type="fig"}B). Moreover, transplantable teratoma blocks generated hematopoietic cells that seeded the BM of *c-Kit*^*Δ/Δ*^ host mice ([Figure 4](#fig4){ref-type="fig"}C). Using this transplantation approach, we are able to shorten hematopoietic cell generation time by 5 weeks, from 10 to 5 weeks ([Figure 4](#fig4){ref-type="fig"}D). The frequency of teratomas that generated CD45.1^+^ blood cells was also higher in the transplanted hosts, compared with injection of iPSCs ([Figure 4](#fig4){ref-type="fig"}E). We also confirmed CD45.1^+^ WBMCs from these hosts could transplant into recipients ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Combined, these data demonstrate that transplantable teratomas constitute stable and continuous sources of hematopoietic cells.Figure 4Transplantation and Freeze Preservation of Teratoma Blocks(A) Strategy transplant and freeze-preserved teratomas for hematopoietic cell formation. Teratomas (26--30 weeks old) were divided into (1.5 × 1.5 × 1.5 cm) blocks and were transplanted into *c-Kit*-deficient mice with 4 weeks of Dox administration (with or without initial freeze preservation), followed by poly(I:C) administration.(B) Average diameter of the transplanted teratoma blocks after transplantation (n = 3).(C) Representative flow cytometric plots for CD45.1 and CD45.2 from the PB of host mice 5--7 weeks after transplantation with *GFG* teratoma blocks (n = 5).(D) Average percentage CD45.1^+^ PB cells in host mice following transplantation with teratoma blocks, frozen blocks, or iPSCs. Data are the means ± SD from two independent experiments (n = 6 iPSCs, n = 16 teratoma blocks, n = 3 frozen blocks).(E) Frequency of teratomas giving rise to CD45.1 PB cells from transplanted iPSCs and teratoma blocks.

Discussion {#sec3}
==========

Here, we report an optimized system to generate HSC *in vivo* via teratoma formation for faster, higher-efficiency HSC production from iPSCs without co-injection of stromal cells or continuous provision of cytokines. While [@bib16] were able to generate HPCs from fibroblasts *in vitro* by overexpressing *GFG*, transplantable HSCs could not be detected. Here, we have demonstrated that within an *in vivo* environment (iPSC-derived teratomas), *GFG* expression generated functional long-term HSCs. Our data therefore highlight the importance of *in vivo* evaluation of directed and transdifferentiation approaches. We envision *in vivo* HSC generation via teratoma formation as an important assay to assess new (and existing) approaches to generate engraftable HSCs. We also highlight the potential of our system to study mechanisms of HSC generation using an *eR1-EGFP* reporter system ([@bib12]). In summary, we demonstrate that *GFG* overexpression *in vivo* within mouse teratomas can generate fully functional HSCs.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

C57BL/6-Ly5.2 (Ly5.2) and C57BL/6-Ly5.1 (Ly5.1) mice were purchased from Japan SLC (Shizuoka, Japan) and Sankyo Lab Service (Tsukuba, Japan), respectively. For generation of *Mx1-Cre c-Kit*^flox/flox^ mice, *c-Kit*^lox66-71/lox66-71^ mice ([@bib7]) were crossed with *Mx1-Cre* mice transgenic mice ([@bib8]). Mice received 250 μg of poly(I:C) intraperitoneally seven times every other day to induce Cre expression. Animal experiments were approved by the Animal Care and Use Committee, Institute of Medical Science, University of Tokyo.

Cell Culture {#sec4.2}
------------

Mouse iPSCs were obtained by reprogramming tail-tip fibroblasts of C57BL/6-Ly5.1 mice with *Oct4*, *Sox2*, and *Klf4*, and then maintained as previously described ([@bib11]).

Lentivirus {#sec4.3}
----------

Inducible lentivirus vectors were derived from the self-inactivating lentiviral vector CS-TRE-PRE-Ubc-tTA-I2G ([@bib26]). Lentiviral production was performed as previously described ([@bib19]).

Reverse Transcription PCR {#sec4.4}
-------------------------

Total RNA was extracted using TRIzol (Invitrogen) and reverse transcribed (High Capacity cDNA RT Kit; Applied Biosystems). qPCR was performed using the Universal Probe Library System (Roche Diagnostics; see [Table S1](#mmc1){ref-type="supplementary-material"}). Samples were normalized to *Gadph* expression, using TaqMan probes (Applied Biosystems).

Teratoma Formation {#sec4.5}
------------------

Two million murine iPSCs were administered subcutaneously into C57BL/6(Ly5.2) or *Mx1-Cre* c*-Kit*^flox/flox^ mice (6--10 weeks old) with Matrigel. We measured teratoma growth every month and analyzed the ratio of CD45.1^+^ cells in PB every month. Where indicated, TF expression was induced after teratoma formation by Dox (2 μg/mL) administration via the water supply for 4 weeks. After 4 weeks of Dox administration, mice received poly(I:C) intraperitoneally.

BM Transplantation Assay {#sec4.6}
------------------------

BM cells (1 × 10^7^) from teratoma-bearing mice were transplanted into lethally irradiated (9.5 Gy) wild-type C57BL/6-Ly5.2 recipient mice. BM cells (1 × 10^7^) from the primary recipient mice were transplanted 16 weeks after primary BM transplantation into lethally irradiated secondary recipients.

Flow Cytometry {#sec4.7}
--------------

PB and BM were stained with anti-mouse antibodies as detailed in [Table S2](#mmc1){ref-type="supplementary-material"}. Analysis was performed on a FACSCanto using Summit software (Beckman Coulter), and the results were analyzed with FlowJo.

Colony Assays {#sec4.8}
-------------

BM cells (20,000) were added to 1.1 mL of MethoCult GF M3434 (STEMCELL Technologies) and cultured at 37°C with 5% CO~2~. Colonies were counted after 11 days, cytospun onto slide glasses, and subjected to Hemacolor staining (Merck) for morphological examination.

Histopathology/Immunohistochemistry {#sec4.9}
-----------------------------------

Histological findings were assessed by H&E-stained sections of paraffin-embedded teratoma tissue. For immunohistochemical analysis of teratomas, sections were stained with anti-Runx1 monoclonal Ab (Abcam92336) followed by anti-rabbit IgG-HRP. Antibody staining was detected by DAB staining followed by counterstaining with hematoxylin. After heating the microscope slides to 95°C for 5 min, sections were stained with anti-CD31 monoclonal Ab (SPRING BIOSCIENCE SP38) followed by anti-rabbit IgG-HRP. Antibody staining was detected by Bajoran Purple Chromogen Kit (Biocare Medical).

3D Teratoma Imaging {#sec4.10}
-------------------

Teratoma clearing protocols were slightly modified from the original CUBIC protocol ([@bib21]). Teratomas were collected and fixed in 4% paraformaldehyde solution for 2 days. For nuclear staining, teratomas were immersed in DAPI/PBS solution at 37°C for 3 days with gentle shaking. Tissues were embedded in 4 mm diameter glass capillaries with 2% agarose for imaging. Images were acquired using a Zeiss Z1 Lightsheet microscope (Zeiss) and reconstituted into 3D images using Zen software (Zeiss).

Statistics {#sec4.11}
----------

Calculations of statistically significant differences between samples using the Student\'s two-tailed t test were performed using Prism 4 software. Error bars displayed are the SD.
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